Overview

Androgen Deprivation Therapy or Androgen Deprivation Therapy Plus Definitive Treatment (Radiation or Surgery)

Status:
Active, not recruiting

Trial end date:
2023-03-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research is to learn if treatment with androgen deprivation therapy in combination with surgery or radiation therapy can prolong the progression-free survival of oligometastatic prostate cancer than androgen deprivation therapy alone. The safety of this treatment combination will also be studied.

Phase:

Phase 2

Details

Lead Sponsor:

Fudan University

Treatments:

Androgens
Ascorbic Acid
Bicalutamide
Estrogens, Conjugated (USP)
Flutamide
Goserelin
Leuprolide
Methyltestosterone
Triptorelin Pamoate